35.8 F
Rhode Island
Monday, January 21, 2019
Home Tags EpiVax Inc.

Tag: EpiVax Inc.

IMMUNOLOGY ADVANCES: Dr. Anne S. De Groot, CEO, and William Martin, chief operating and information officer, co-founded biotech company EpiVax, which has made advances in computational immunology – a branch of medicine covering the human immune system – genomics and vaccine design.

EpiVax on cutting edge of research

EpiVax Inc.’s motto is “science without fear.”From its new headquarters in the Rising Sun Mills complex, a former wool mill in Olneyville, the privately...
EPIVAX WILL celebrate its 20th anniversary in a new Olneyville office at 166 Valley St. June 15.

EpiVax moves growing staff to Olneyville

PROVIDENCE — Immunology engineering biotech firm EpiVax Inc. continues an eventful anniversary year with a new headquarters at 188 Valley St. in the Rising...
IMMUNOLOGY ENGINEERING BIOTECH firm EpiVax will use Small Business Innovation Research funding to develop a Tregitrope-biotherapeutic intended to restore immunological balance in Graves’ disease patients.

New EpiVax innovation could target Graves’ disease

PROVIDENCE — The first target of immunology engineering biotech firm EpiVax Inc.’s latest antigen-specific therapies? Graves’ disease, an auto-immune condition that results in hypothyroidism.Current...
TEAM MEETING: From left, Brenton DeBoef, professor of chemistry at the University of Rhode Island, and Alcinous Pharmaceutical team members Nicholas DaSilva, CEO and Ph.D. student in the URI College of Pharmacy; Benjamin Barlock, chief technology officer and Ph.D. student in the URI College of Pharmacy; David Worthen, chief operations officer and URI assistant professor in the Department of Biomedical and Pharmaceutical Sciences and the Department of Chemical Engineering; and Ken Rose, chief scientific officer and Ph.D. student in the URI College of Pharmacy, discuss Alcinous’ latest research project. / PBN PHOTO/RUPERT WHITELEY

Alcinous to use $50K Innovation Voucher to create new PARP inhibitor

Five weeks prior to celebrating its first year in business, Alcinous Pharmaceuticals received a $50,000 Innovation Voucher from R.I. Commerce Corp.The microcompany had been...
EPIVAX PRESIDENT AND CEO Dr. Anne S. De Groot. EpiVax has launched a venture-backed spinoff, Epivax Oncology. / PBN FILE PHOTO

EpiVax launches EpiVax Oncology for personalized cancer vaccines

PROVIDENCE — Immunolgy engineering biotech firm EpiVax Inc. has launched EpiVax Oncology Inc., a venture-backed spinoff focused on the development of personalized therapeutic cancer...
EPIVAX PRESIDENT AND CEO Dr. Anne S. De Groot. EpiVax has joined an National Institutes of Health partnership to research a vaccine for the influenza A (H7N9) virus. / PBN FILE PHOTO/MICHAEL SALERNO

EpiVax leads NIH’s $5.8M bird-flu vaccine project

PROVIDENCE - Immunolgy engineering biotech firm EpiVax Inc. is leading a National Institutes of Health-funded $5.8 million collaboration developing a protective vaccine against avian influenza...
COMMERCE SECRETARY Stefan Pryor is proud to participate in the sixth round of Innovation Vouchers, in which the R.I. Commerce Corp. and Gov. Gina M. Raimondo, in partnership with the General Assembly, awarded $193,668 to four R.I. companies. / PBN FILE PHOTO/MICHAEL SALERNO

Gov. Raimondo, Commerce RI award $193,668 in Innovation Vouchers

Updated at 1:01 p.m.PROVIDENCE - Four more companies were awarded $193,668 in innovation grants by the R.I. Commerce Corp., Gov. Gina M. Raimondo announced...
EPIVAX INC. HAS updated its logo to a more modern design in celebration of the 19th anniversary since the biotechnology company's incorporation in 1998.

EpiVax updates logo to celebrate 19th anniversary

PROVIDENCE – Biotechnology company EpiVax Inc. celebrated its 19th year in business this month with an updated logo and a tease of “other surprises”...
Nick Inglis

Five Questions With: Nick Inglis

Nick Inglis is the president of the Information Coalition and co-founder of the Information Governance Conference, held annually in Providence. Inglis answers PBN’s questions...
EPIVAX CEO Anne S. De Groot said "tregitope is likely to be an important new tool for clinicians who wish to improve the lives of patients."

EpiVax licenses tregitope technology to global pharmaceutical firm

PROVIDENCE – EpiVax Inc. said Tuesday it has licensed its immune-modulating technology to a global pharmaceutical company to treat autoimmune disease and allergies.The biotechnology...
- Featured Event -

Latest News

Our panel of health care experts and business leaders will provide insights into the future of health care reform, improving health care delivery and reducing health care waste and costs, while also addressing preventative care, population health and the opioid epidemic.

2018 Fall Health Care Summit

Tuesday October 30, 2018

Crowne Plaza Grand Ballroom